Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum

スポンサーリンク

概要

論文の詳細を見る
B cell lymphomas often develop in the centralnervous system (CNS). Although rituximab (RTX) hasbeen widely used for most B cell lymphomas, the efficacyfor CNS lymphomas has yet to be elucidated. A majorconcern is that RTX might not reach lymphoma lesions,and either the antibody-dependent cellular cytotoxicity orcomplement-dependent cytotoxicity might not substantiallyoperate in the CNS environment. Here we investigatedthe potential usefulness of co-administering RTX andhuman serum intraventricularly in nude rats carryinghuman B cell lymphomas in the CNS. Raji, a CD20-positivelymphoma cell line, was inoculated into the cerebrumof F344 (rnu/rnu) nude rats. After several days, RTX andhuman serum were delivered into the ipsilateral lateralventricle via a cannula. Intraventricularly administeredRTX was localized specifically at the lymphoma lesions,indicating that RTX penetrated the ependymal layer of thelateral ventricle to reach the tumor lesion, where it specificallybound to the lymphoma cells. The combination ofRTX and serum (n = 12), but not RTX alone (n = 13),significantly extended the survival of the rats (P = 0.049).Intraventricular administration of RTX and serum in arat/human CNS lymphoma model might be a potentialnovel treatment for CNS lymphomas of B cell origin.Clinical trials are warranted.
日本血液学会の論文
2010-10-15

著者

関連論文

Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum

スポンサーリンク